Free tool
Stocks listed on Nasdaq GS
We cover 147 companies listed on Nasdaq GS. The median market value in the group is $4.92B. Across the group, the median move over the past trading day is −0.33%. 75% of the 141 with a 200-day average trade above it. Price change over the past year runs from −30.6% to +246.9% across the middle 80 percent of the group, with a median of +44.7%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
147 of 1,279 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| AMGN | Amgen Inc. | $238.06B | Mega cap | +56.24% |
| GILD | Gilead Sciences, Inc. | $184.47B | Large cap | +32.51% |
| VRTX | Vertex Pharmaceuticals Incorporated | $138.63B | Large cap | +40.66% |
| ISRG | Intuitive Surgical, Inc. | $133.22B | Large cap | −21.38% |
| SNY | Sanofi | $108.83B | Large cap | −4.33% |
| REGN | Regeneron Pharmaceuticals, Inc. | $83.89B | Large cap | +39.36% |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% |
| MRNA | Moderna, Inc. | $59.75B | Large cap | +496.25% |
| NTRA | Natera, Inc. | $48.53B | Large cap | +107.59% |
| MDLN | Medline Inc. | $46.53B | Large cap | −13.07% |
| RVMD | Revolution Medicines, Inc. | $46.18B | Large cap | +466.35% |
| IDXX | IDEXX Laboratories, Inc. | $43.66B | Large cap | −13.64% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +25.21% |
| RPRX | Royalty Pharma plc | $35.71B | Large cap | +74.00% |
| ILMN | Illumina, Inc. | $33.95B | Large cap | +125.88% |
| DXCM | DexCom, Inc. | $33.65B | Large cap | +16.47% |
| GEHC | GE HealthCare Technologies Inc. | $33.35B | Large cap | −1.15% |
| BIIB | Biogen Inc. | $32.66B | Large cap | +62.12% |
| ALNY | Alnylam Pharmaceuticals, Inc. | $32.12B | Large cap | −47.38% |
| BNTX | BioNTech SE | $28.28B | Large cap | +9.27% |
| INSM | Insmed Incorporated | $27.16B | Large cap | −7.54% |
| ROIV | Roivant Sciences Ltd. | $26.55B | Large cap | +206.51% |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% |
| GH | Guardant Health, Inc. | $22.94B | Large cap | +169.17% |
| GMAB | Genmab A/S | $21.42B | Large cap | +36.20% |
| VTRS | Viatris Inc. | $19.35B | Large cap | +66.19% |
| MEDP | Medpace Holdings, Inc. | $17.28B | Large cap | +30.74% |
| JAZZ | Jazz Pharmaceuticals plc | $16.89B | Large cap | +100.35% |
| ASND | Ascendis Pharma A/S | $16.41B | Large cap | +29.66% |
| NBIX | Neurocrine Biosciences, Inc. | $15.92B | Large cap | +13.36% |
| BBIO | BridgeBio Pharma, Inc. | $15.52B | Large cap | +60.05% |
| COO | The Cooper Companies, Inc. | $14.25B | Large cap | −1.93% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% |
| ICLR | ICON Public Limited Company | $13.03B | Large cap | −2.91% |
| BMRN | BioMarin Pharmaceutical Inc. | $12.70B | Large cap | +11.85% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.52B | Large cap | +308.99% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.45B | Large cap | +26.78% |
| HALO | Halozyme Therapeutics, Inc. | $12.41B | Large cap | +46.30% |
| TEM | Tempus AI, Inc. | $12.40B | Large cap | −6.49% |
| TECH | Bio-Techne Corporation | $11.35B | Large cap | +29.33% |
| BTSG | BrightSpring Health Services, Inc. | $11.32B | Large cap | +156.37% |
| ALGN | Align Technology, Inc. | $11.31B | Large cap | +12.09% |
| CYTK | Cytokinetics, Incorporated | $11.01B | Large cap | +109.36% |
| KRYS | Krystal Biotech, Inc. | $10.65B | Large cap | +143.67% |
| IONS | Ionis Pharmaceuticals, Inc. | $10.56B | Large cap | +48.21% |
| PRAX | Praxis Precision Medicines, Inc. | $10.54B | Large cap | +704.28% |
| ENSG | The Ensign Group, Inc. | $10.43B | Large cap | +5.01% |
| HSIC | Henry Schein, Inc. | $10.30B | Large cap | +31.02% |
| RGEN | Repligen Corporation | $10.25B | Large cap | +51.67% |
| PODD | Insulet Corporation | $9.94B | Mid cap | −57.12% |
| TWST | Twist Bioscience Corporation | $9.41B | Mid cap | +451.89% |
| PCVX | Vaxcyte, Inc. | $9.09B | Mid cap | +99.97% |
| IMVT | Immunovant, Inc. | $9.07B | Mid cap | +189.13% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% |
| HQY | HealthEquity, Inc. | $8.75B | Mid cap | +18.69% |
| BRKR | Bruker Corporation | $8.69B | Mid cap | +70.56% |
| TXG | 10x Genomics, Inc. | $8.37B | Mid cap | +358.35% |
| ALKS | Alkermes plc | $8.25B | Mid cap | +68.07% |
| SYRE | Spyre Therapeutics, Inc. | $8.13B | Mid cap | +446.12% |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −29.83% |
| SRRK | Scholar Rock Holding Corporation | $7.31B | Mid cap | +74.18% |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% |
| ERAS | Erasca, Inc. | $6.70B | Mid cap | +1112.03% |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +196.85% |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.27B | Mid cap | +92.20% |
| PTCT | PTC Therapeutics, Inc. Common Stock | $6.07B | Mid cap | +46.02% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.05B | Mid cap | +133.47% |
| DFTX | Definium Therapeutics, Inc. | $5.88B | Mid cap | +344.37% |
| SHC | Sotera Health Company | $5.58B | Mid cap | +18.42% |
| MMED | MiniMed Group, Inc. | $5.48B | Mid cap | +5.41% |
| MMSI | Merit Medical Systems, Inc. | $5.44B | Mid cap | −0.28% |
| GRFS | Grifols, S.A. | $5.38B | Mid cap | −19.39% |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.07B | Mid cap | +11.33% |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +93.26% |
| EWTX | Edgewise Therapeutics, Inc. | $4.80B | Mid cap | +207.13% |
| LFST | LifeStance Health Group, Inc. | $4.69B | Mid cap | +121.31% |
| WAY | Waystar Holding Corp. | $4.63B | Mid cap | −34.97% |
| BLLN | BillionToOne, Inc. | $4.54B | Mid cap | −11.68% |
| ICUI | ICU Medical, Inc. | $4.49B | Mid cap | +41.83% |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% |
| LIVN | LivaNova PLC | $4.41B | Mid cap | +41.56% |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | +40.79% |
| INDV | Indivior Pharmaceuticals, Inc. | $4.23B | Mid cap | +47.06% |
| ADPT | Adaptive Biotechnologies Corporation | $4.18B | Mid cap | +101.70% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% |
| IRTC | iRhythm Holdings, Inc. | $4.06B | Mid cap | −29.83% |
| LEGN | Legend Biotech Corporation | $4.02B | Mid cap | −40.44% |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% |
| DNLI | Denali Therapeutics Inc. | $3.98B | Mid cap | +57.50% |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | +181.38% |
| TLX | Telix Pharmaceuticals Limited | $3.77B | Mid cap | −8.02% |
| OPCH | Option Care Health, Inc. | $3.60B | Mid cap | −15.91% |
| GRAL | GRAIL, Inc. | $3.55B | Mid cap | +136.66% |
| QURE | uniQure N.V. | $3.53B | Mid cap | +223.49% |
| MRVI | Maravai LifeSciences Holdings, Inc. | $3.30B | Mid cap | +281.97% |
| MBX | MBX Biosciences, Inc. | $3.22B | Mid cap | +366.53% |
| BEAM | Beam Therapeutics Inc. | $3.21B | Mid cap | +79.06% |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.12B | Mid cap | +60.64% |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.10B | Mid cap | +22.19% |
| ALMS | Alumis Inc. | $3.06B | Mid cap | +380.08% |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +73.50% |
| ALHC | Alignment Healthcare, Inc. | $2.88B | Mid cap | −13.88% |
| ACHC | Acadia Healthcare Company, Inc. | $2.85B | Mid cap | +37.81% |
| PRVA | Privia Health Group, Inc. | $2.71B | Mid cap | −3.13% |
| WGS | GeneDx Holdings Corp. | $2.69B | Mid cap | −30.11% |
| PGEN | Precigen, Inc. | $2.65B | Mid cap | +61.66% |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.61B | Mid cap | −12.10% |
| PHVS | Pharvaris N.V. | $2.60B | Mid cap | +55.59% |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +103.83% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.51B | Mid cap | +15.38% |
| KLRA | Kailera Therapeutics, Inc. | $2.39B | Mid cap | −29.08% |
| ALMR | Alamar Biosciences, Inc. | $2.36B | Mid cap | +54.91% |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.30B | Mid cap | +44.68% |
| MLYS | Mineralys Therapeutics, Inc. | $2.28B | Mid cap | +70.22% |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% |
| CLOV | Clover Health Investments, Corp. | $2.26B | Mid cap | +57.99% |
| ADUS | Addus HomeCare Corporation | $2.25B | Mid cap | +4.50% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +4.47% |
| XRAY | DENTSPLY SIRONA Inc. | $2.18B | Mid cap | −21.61% |
| ZBIO | Zenas BioPharma, Inc. | $2.15B | Mid cap | +97.73% |
| HCM | HUTCHMED (China) Limited | $2.15B | Mid cap | −17.45% |
| STOK | Stoke Therapeutics, Inc. | $2.14B | Mid cap | +71.45% |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% |
| NVCR | NovoCure Limited | $2.08B | Mid cap | +50.21% |
| GENB | Generate Biomedicines, Inc. | $2.07B | Mid cap | +27.59% |
| SRPT | Sarepta Therapeutics, Inc. | $2.06B | Mid cap | +7.69% |
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | $2.03B | Mid cap | −13.45% |
| CMPS | COMPASS Pathways plc | $2.02B | Mid cap | +209.53% |
| ATRA | Atara Biotherapeutics, Inc. | $94.15M | Micro cap | −24.05% |
| CVRX | CVRx, Inc. | $87.12M | Micro cap | −56.75% |
| GOSS | Gossamer Bio, Inc. | $85.01M | Micro cap | −92.93% |
| DH | Definitive Healthcare Corp. | $84.34M | Micro cap | −80.44% |
| OM | Outset Medical, Inc. | $79.89M | Micro cap | −69.56% |
| PLRX | Pliant Therapeutics, Inc. | $73.69M | Micro cap | −31.36% |
| SPRO | Spero Therapeutics, Inc. | $71.05M | Micro cap | −38.38% |
| XBIT | XBiotech Inc. | $70.43M | Micro cap | −33.62% |
| PMVP | PMV Pharmaceuticals, Inc. | $70.03M | Micro cap | −7.75% |
| BOLD | Boundless Bio, Inc. | $66.31M | Micro cap | +155.70% |
| MCRB | Seres Therapeutics, Inc. | $47.81M | Micro cap | −74.79% |
| MGX | Metagenomi Therapeutics, Inc. | $46.09M | Micro cap | −34.41% |
| KPTI | Karyopharm Therapeutics Inc. Common Stock | $44.46M | Micro cap | −74.90% |
| PETS | PetMed Express, Inc. | $38.81M | Micro cap | −43.35% |
| KYNB | Kyntra Bio, Inc. | $32.82M | Micro cap | −22.66% |
| QNCX | Quince Therapeutics, Inc. | $31.84M | Micro cap | +100.71% |
| NXTC | NextCure, Inc. | $27.05M | Micro cap | +11.37% |
| TXMD | TherapeuticsMD, Inc. | $26.39M | Micro cap | +103.57% |
| TRIB | Trinity Biotech plc | $7.80M | Micro cap | +547.97% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.